All In Biotech

Free tool

FAERS Monitor: Jentadueto

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201281 or its brand name (Jentadueto, Linagliptin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,201

Serious

655

55% of reports

Hospitalization

343

Death reported

52

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased93
  • diarrhoea90
  • nausea67
  • vomiting58
  • drug ineffective53
  • fatigue45
  • off label use45
  • pain43
  • dizziness42
  • headache41
  • arthralgia40
  • acute kidney injury38
  • asthenia37
  • pain in extremity34
  • dyspnoea33

Reports by year received

View as table
YearReports
201238
201379
2014106
2015118
2016111
2017116
2018109
2019115
202072
202182
202268
202364
202462
202539
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood glucose increasedSignal938.67.1627
acute kidney injurySignal384.33.295
diarrhoeaSignal902.42.078
vomitingSignal582.21.736
pain in extremitySignal342.01.517
asthenia371.71.311
arthralgia401.71.211
nausea671.51.210
dizziness421.51.16
pain431.20.92
headache411.10.81
dyspnoea331.00.70
fatigue451.00.80
off label use450.90.70
drug ineffective530.70.57

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.